LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...

Terumo's Spectra Optia® Apheresis System Terumo's Spectra Optia® Apheresis System LAKEWOOD, Colo., U.S., and SANTA ROSA, Calif., U.S., July 27, 2022 (GLOBE NEWSWIRE) -- Acute kidney injury (AKI) and ...

The company identified 7 studies from the clinical evidence search which incorporated an economic analysis. However, it was unable to draw any firm conclusions from these studies. The external ...

New connectivity captures data at its source, reducing manual burden and enabling broader value across patient care, research and biopharma collaboration FREMONT, Calif., April 21, 2026 ...

Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia(R) Apheresis System at major conferences Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and ...

LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ -- Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the Spectra Optia ® Apheresis ...

[Updated] The Bermuda Hospitals Board has launched service of the Spectra Optia therapeutic apheresis machine, with the BHB saying that Bermuda’s sickle cell patients are now better served thanks to ...

Designed for use in intensive care units, the system includes Terumo BCT’s Spectra Optia Apheresis device and filters developed by Marker Therapeutics AG. (Terumo) () The FDA has granted an emergency ...

In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...